MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“The proto-oncogene MET, which enforces hepatocyte growth factor receptor (HGFR, also known as MET tyrosine kinase receptor), shares several downstream pathways with EGFR, including RAS/RAF/MAPK and PI3K/AKT signaling pathways [173,183].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [14]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Research works printed but not linked: 2
- J. G. Christensen et al., Cancer Res.63, 7345 (2003).
- F. M. Yakes et al., Cancer Res.62, 4132 (2002).
Cited by
Items 801–900 of 1,038
Tan, Y. C., Krishnaswamy, S., Nandi, S., Kanteti, R., Vora, S., Onel, K., Hasina, R., Lo, F.-Y., El‐Hashani, E., Cervantes, G. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008972 · Cited by 112
Curcumin: Updated Molecular Mechanisms and Intervention Targets in Human Lung Cancer
Ye, M.-X., Li, Y., Yin, H., & Zhang, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13033959 · Cited by 109
Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors
Segatto, O., Anastasi, S., & Alemà, S. (2011) · Journal of Cell Science · doi:10.1242/jcs.083303 · Cited by 103
Mirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0099 · Cited by 114
Xu, S., Lou, F., Wu, Y., Sun, D., Zhang, J., Chen, W., Ye, H., Liu, J.-H., Wei, S., Zhao, M., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.005 · Cited by 108
Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103
Socinski, M. A., Pennell, N. A., & Davies, K. D. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00516 · Cited by 141
Yonesaka, K., Tanizaki, J., Maenishi, O., Haratani, K., Kawakami, H., Tanaka, K., Hayashi, H., Sakai, K., Chiba, Y., Tsuya, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3359 · Cited by 110
Toschi, L., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0071 · Cited by 103
Self-citationTargeted Therapies for Lung Cancer: Clinical Experience and Novel Agents
Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 103
Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.257 · Cited by 102
Self-citationKim, C., Hoang, C. D., Kesarwala, A. H., Schrump, D. S., Guha, U., & Rajan, A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.012 · Cited by 104
MET: roles in epithelial-mesenchymal transition and cancer stemness
Jeon, H.-M., & Lee, J. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.67 · Cited by 113
Yue, J., Lv, D., Wang, C., Li, L., Zhao, Q., Chen, H., & Xu, L. (2018) · Oncogene · doi:10.1038/s41388-018-0276-2 · Cited by 107
Lei, H., & Kazlauskas, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808426200 · Cited by 102
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer
Park, K., Kim, H., Lee, J.-H., Choi∥, Y., Park∥, S., Yang, S., Kim, S., & Hong, K. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0681-6 · Cited by 102
Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
Blanc, J., Geney, R., & Menet, C. J. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313050008 · Cited by 111
The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 118
Andersen, A. P., Moreira, J. M. A., & Pedersen, S. F. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0098 · Cited by 109
Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
Gao, W., Wang, M. L., Wang, L., Lu, H., Wu, S., Dai, B., Ou, Z., Zhang, L., Heymach, J. V., Gold, K. A., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju204 · Cited by 105
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Pennell, N. A., & Lynch, T. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0276 · Cited by 101
Insight into the Role of Wnt5a-Induced Signaling in Normal and Cancer Cells
Endo, M., Nishita, M., Fujii, M., & Minami, Y. (2014) · International review of cytology · doi:10.1016/bs.ircmb.2014.10.003 · Cited by 108
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 101
Yonesaka, K., Takegawa, N., Watanabe, S., Haratani, K., Kawakami, H., Sakai, K., Chiba, Y., Maeda, N., Kagari, T., Hirotani, K., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0517-4 · Cited by 103
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 114
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Garrett, J. T., Sutton, C. R., Kuba, M. G., Cook, R. S., & Arteaga, C. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2024 · Cited by 108
c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Stabile, L. P., He, G., Lui, V. W. Y., Thomas, S. M., Henry, C. L., Gubish, C. T., Joyce, S. C., Quesnelle, K. M., Siegfried, J. M., & Grandis, J. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1555 · Cited by 103
Gaughan, E. M., & Costa, D. B. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010397569 · Cited by 113
Sung, Y., Liu, Y.-C., Chao, P., Chang, C.-C., Jin, P.-R., Lin, T.-T., Lin, J.-A., Cheng, H., Wang, J., Lai, C. P., et al. (2017) · Theranostics · doi:10.7150/thno.21168 · Cited by 108
Yamada, T., Matsumoto, K., Wang, W., Li, Q., Nishioka, Y., Sekido, Y., Sone, S., & Yano, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1204 · Cited by 108
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
Yuan, T. L., Choi, H. S., Matsui, A., Benes, C., Lifshits, E., Luo, J., Frangioni, J. V., & Cantley, L. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804123105 · Cited by 99
Self-citationPerk, L. R., van Walsum, M., Visser, G. W. M., Kloet, R. W., Vosjan, M. J. W. D., Leemans, C. R., Giaccone, G., Albano, R., Comoglio, P. M., & van Dongen, G. A. M. S. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0774-5 · Cited by 99
MET Signaling Pathway: A Rational Target for Cancer Therapy
Appleman, L. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7929 · Cited by 99
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Sharma, G. G., Mota, I. A., Mologni, L., Patrucco, E., Gambacorti-Passerini, C. B., & Chiarle, R. (2018) · Cancers · doi:10.3390/cancers10030062 · Cited by 106
Feng, C., Zhao, Y., Li, Y., Zhang, T., Ma, Y., & Liu, Y. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.03.018 · Cited by 103
HER3 in cancer: from the bench to the bedside
Gandullo‐Sánchez, L., Ocaña, A., & Pandiella, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02515-x · Cited by 115
EGFR/Met association regulates EGFR TKI resistance in breast cancer
Mueller, K. L., Yang, Z.-Q., Haddad, R., Ethier, S. P., & Boerner, J. L. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-8 · Cited by 99
Quantifying EGFR Alterations in the Lung Cancer Genome with Nanofluidic Digital PCR Arrays
Wang, J., Ramakrishnan, R., Tang, Z., Fan, W., Kluge, A., Dowlati, A., Jones, R. C., & Ma, P. C. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.134973 · Cited by 107
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
“MET amplification leads to the reactivation of this pathway by forming a MET-ErbB-3 heterodimer.(28) Thus, despite continuous suppression of EGFR by the inhibitor, a critical downstream signaling pathway is reactivated, and resistance to the inhibitor emerges.”
BackgroundThe evolving genomic classification of lung cancer
Shames, D. S., & Wistuba, I. I. (2014) · The Journal of Pathology · doi:10.1002/path.4275 · Cited by 98
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Yu, H. A., & Riely, G. J. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0024 · Cited by 104
Yeh, P., Chen, H., Andrews, J., Naser, R., Pao, W., & Horn, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1894 · Cited by 98
Li, W., Ma, X., Li, N., Liu, H., Dong, Q., Zhang, J., Yang, C., Liu, Y., Liang, Q., Zhang, S., et al. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.11.002 · Cited by 103
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
Bertotti, A., Burbridge, M. F., Gastaldi, S., Galimi, F., Torti, D., Medico, E., Giordano, S., Corso, S., Rolland-Valognes, G., Lockhart, B. P., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000643 · Cited by 97
Schüler, M., Berardi, R., Lim, W., de Jonge, M. J. A., Bauer, T. M., Azaro, A., Gottfried, M., Han, J., Lee, D. H., Wollner, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.293 · Cited by 105
Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1
Chen, Z., Chen, Q., Cheng, Z., Gu, J., Feng, W.-Y., Lei, T., Huang, J., Pu, J., Chen, X., & Wang, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03047-y · Cited by 106
Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I. S., Plotnick, D. O., Udagawa, H., Izumi, H., Shibata, Y., Tanaka, K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2811 · Cited by 118
Wang, T., Liu, Z., She, Y., Deng, J., Zhong, Y., Zhao, M., Li, S., Xie, D., Sun, X., Hu, X., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.007 · Cited by 101
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 110
Watanabe, K., Emoto, N., Hamano, E., Sunohara, M., Kawakami, M., Kage, H., Kitano, K., Nakajima, J., Goto, A., Fukayama, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26254 · Cited by 100
Wang, Y., Fukuda, T., Isaji, T., Lu, J., Im, S., Hang, Q., Gu, W., Hou, S., Ohtsubo, K., & Gu, J. (2015) · The FASEB Journal · doi:10.1096/fj.15-270710 · Cited by 100
Yoshida, T., Song, L., Bai, Y., Kinose, F., Li, J., Ohaegbulam, K. C., Muñoz-Antonia, T., Qu, X., Eschrich, S., Uramoto, H., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147344 · Cited by 96
Breakthrough in targeted therapy for non-small cell lung cancer
Zhencong, Y., Huang, Y., Ke, J., Zhu, X. M., Leng, S., & Luo, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111079 · Cited by 105
Gene amplification: mechanisms and involvement in cancer
Matsui, A., Ihara, T., Suda, H., Mikami, H., & Semba, K. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0026 · Cited by 116
Surgery for NSCLC in the era of personalized medicine
Mitsudomi, T., Suda, K., & Yatabe, Y. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.22 · Cited by 102
Self-citationLeidner, R. S., Fu, P., Clifford, B. T., Hamdan, A., Jin, C., Eisenberg, R., Boggon, T. J., Skokan, M. C., Franklin, W. A., Cappuzzo, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1431 · Cited by 98
Self-citationCevenini, A., Orrù, S., Mancini, A., Alfieri, A., Buono, P., & Imperlini, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082411 · Cited by 95
Epithelial-mesenchymal transition
Zhang, C. X., Huang, R. Y., Sheng, G., & Thiery, J. P. (2025) · Cell · doi:10.1016/j.cell.2025.08.033 · Cited by 134
Tanaka, H., & Yao, M.-C. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2591 · Cited by 101
Benavente, S., Huang, S., Armstrong, E. A., Chi, A., Hsu, K.-T., Wheeler, D. L., & Harari, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2068 · Cited by 95
EGFR mutations in lung cancer: from tissue testing to liquid biopsy
Fenizia, F., Luca, A. D., Pasquale, R., Sacco, A., Forgione, L., Lambiase, M., Iannaccone, A., Chicchinelli, N., Franco, R., Rossi, A., et al. (2015) · Future Oncology · doi:10.2217/fon.15.23 · Cited by 99
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer
Feng, Y., Thiagarajan, P. S., & Ma, P. C. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182417e44 · Cited by 98
Li, W., Ren, S., Li, J., Li, A., Fan, L., Li, X., Zhao, C., He, Y., Gao, G., Chen, X., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.011 · Cited by 96
Abe, Y., & Tanaka, N. (2016) · BioMed Research International · doi:10.1155/2016/7969286 · Cited by 103
A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 102
Acquired Resistance to Drugs Targeting Tyrosine Kinases
Rosenzweig, S. A. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.003 · Cited by 97
Reis, H., Metzenmacher, M., Goetz, M., Savvidou, N., Darwiche, K., Aigner, C., Herold, T., Eberhardt, W., Skiba, C., Hense, J., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.010 · Cited by 97
Sun, W., Chen, X., Xie, C. L., Wang, Y., Lin, L., Zhu, K., & Shuai, X. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00272 · Cited by 100
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Luna, J., Boni, J., Cuatrecasas, M., Ros, X. B., Núñez-Manchón, E., Gironella, M., Vaquero, E. C., Arbonés, M. L., de la Luna, S., & Fillat, C. (2018) · Gut · doi:10.1136/gutjnl-2018-316128 · Cited by 97
Curcumin as tyrosine kinase inhibitor in cancer treatment
Golonko, A., Lewandowska, H., Świsłocka, R., Jasińska, U., Priebe, W., & Lewandowski, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.015 · Cited by 100
Timpson, P., Wilson, A. S., Lehrbach, G. M., Sutherland, R. L., Musgrove, E. A., & Daly, R. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0798 · Cited by 94
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma
Taniguchi, E., Nishijo, K., McCleish, A. T., Michalek, J. E., Grayson, M. H., Infante, A. J., Abboud, H. E., LeGallo, R. D., Qualman, S. J., Rubin, B. P., et al. (2008) · Oncogene · doi:10.1038/onc.2008.255 · Cited by 100
Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor
Reznik, T. E., Sang, Y., Ma, Y., Abounader, R., Rosen, E. M., Xia, S., & Laterra, J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0236 · Cited by 94
Plenker, D., Bertrand, M., de Langen, A. J., Riedel, R. F., Lorenz, C., Scheel, A. H., Müller, J. N., Brägelmann, J., Daßler‐Plenker, J., Kobe, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3001 · Cited by 101
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05626-2 · Cited by 93
GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
Rix, L. L. R., Kuenzi, B. M., Luo, Y., Remily-Wood, E. R., Kinose, F., Wright, G. M., Li, J., Koomen, J. M., Haura, E. B., Lawrence, H. R., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400660a · Cited by 93
Montero, J. C., Esparís-Ogando, A., Re-Louhau, M. F., Seoane, S., Abad, M., Calero, R., Ocaña, A., & Pandiella, A. (2012) · Oncogene · doi:10.1038/onc.2012.572 · Cited by 97
Cooperative, Nanoparticle‐Enabled Thermal Therapy of Breast Cancer
Shen, H., You, J., Zhang, G., Ziemys, A., Li, Q., Bai, L., Deng, X., Erm, D. R., Liu, X., Li, C., et al. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201100005 · Cited by 93
Wright, N. A., & Goss, G. D. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.06.01 · Cited by 104
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Yang, M., Cui, M., Sun, Y., Liu, S., & Jiang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01711-w · Cited by 109
Jun, H. J., Acquaviva, J., Chi, D., Lessard, J., Zhu, H., Woolfenden, S., Bronson, R. T., Pfannl, R., White, F., Housman, D. E., et al. (2011) · Oncogene · doi:10.1038/onc.2011.474 · Cited by 100
Xu, L., Nilsson, M. B., Saintigny, P., Cascone, T., Herynk, M. H., Du, Z., Nikolinakos, P. G., Yang, Y., Prudkin, L., Liu, D., et al. (2010) · Oncogene · doi:10.1038/onc.2010.16 · Cited by 93
Yano, A., Tsutsumi, S., Soga, S., Lee, M.-J., Trepel, J., Osada, H., & Neckers, L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805354105 · Cited by 93
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
Drake, J. M., Lee, J. K., & Witte, O. N. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01592-13 · Cited by 103
Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Fernandez‐Cuesta, L., & Thomas, R. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0854 · Cited by 99
Cheng, H., Zhang, Z., Rodriguez-Barrueco, R., Borczuk, A., Liu, H., Yu, J., Silva, J. M., Cheng, S. K., Perez-Soler, R., & Halmos, B. (2016) · Oncotarget · doi:10.18632/oncotarget.6721 · Cited by 92
Seiwert, T. Y., Sarantopoulos, J., Kallender, H., McCallum, S. W., Keer, H. N., & Blumenschein, G. R. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9861-3 · Cited by 95
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
Kondo, S., Ojima, H., Tsuda, H., Hashimoto, J., Morizane, C., Ikeda, M., Ueno, H., Tamura, K., Shimada, K., Kanai, Y., et al. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0361-9 · Cited by 97
Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
Baker, A. T., Zlobin, A., & Osipo, C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00360 · Cited by 99
Chen, H., Yao, W., Chu, Q., Han, R., Wang, Y., Sun, J., Wang, D., Wang, Y., Cao, M., & He, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.024 · Cited by 97
LoRusso, P., Jänne, P. A., Oliveira, M., Rizvi, N., Malburg, L., Keedy, V., Yee, L., Copigneaux, C., Hettmann, T., Wu, C.-Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3051 · Cited by 92
Self-citationJiang, X., Lü, W., Shen, X., Wang, Q., Lv, J., Liu, M., Cheng, F., Zhao, Z., & Pang, X. (2018) · JCI Insight · doi:10.1172/jci.insight.98921 · Cited by 94
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Agarwal, S., Zerillo, C. A., Kolmakova, J., Christensen, J. G., Harris, L. N., Rimm, D. L., DiGiovanna, M. P., & Stern, D. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604937 · Cited by 104
Self-citationCorso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 92
Epithelial Mesenchymal Transition in Aggressive Lung Cancers
Mittal, V. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_3 · Cited by 106
Sellmann, C., Doerner, A., Knuehl, C., Rasche, N., Sood, V., Krah, S., Rhiel, L., Messemer, A., Wesolowski, J., Schuette, M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753491 · Cited by 91
Oxidation, glycation and glycoxidation—The vicious cycle and lung cancer
Ahmad, S., Khan, M. Y., Rafi, Z., Khan, H., Siddiqui, Z., Rehman, S., Shahab, U., Khan, M. S., Saeed, M., Alouffi, S., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.005 · Cited by 91
Peled, N., Wynes, M. W., Ikeda, N., Ohira, T., Yoshida, K., Qian, J., Ilouze, M., Brenner, R. M., Kato, Y., Mascaux, C., et al. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0133-9 · Cited by 93
Metadata
- Authors
- Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., & Jänne, P. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- ORCID
- Venue
- Science
- Published
- 2007-05-18
- Volume
- 316
- Issue
- 5827
- Pages
- 1039-1043
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1998971866
- Cited by
- 4,496
- References
- 22
- Citations by year
- 2026: 97 · 2025: 109 · 2024: 123 · 2023: 136 · 2022: 152 · 2021: 191 · 2020: 182 · 2019: 214 · 2018: 269 · 2017: 288 · 2016: 291 · 2015: 375 · 2014: 349 · 2013: 369 · 2012: 345
- FWCI
- 207.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca111560-05)
- National Cancer Institute (R01-CA111560, P01CA089021, R01CA114465, P20CA090578, P20 CA 90578-02, 1K12CA87723-01, K08CA120060, K12CA087723)
- National Institute of General Medical Sciences (GM 41890, R01GM041890)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MET amplification, gefitinib resistance, lung cancer, HER3, PI3K signaling, EGFR kinase inhibitors, erlotinib, drug resistance, ErbB receptors, MET oncogene
- MeSH terms
- Gefitinib, Proto-Oncogene Mas, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cricetulus, Enzyme Inhibitors, Gene Amplification, Cricetinae, Humans, Indoles, Lung Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Sulfones, Signal Transduction, CHO Cells, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Receptor, ErbB-3, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.